WO1995007282A1 - Depression remedy - Google Patents
Depression remedy Download PDFInfo
- Publication number
- WO1995007282A1 WO1995007282A1 PCT/JP1994/001455 JP9401455W WO9507282A1 WO 1995007282 A1 WO1995007282 A1 WO 1995007282A1 JP 9401455 W JP9401455 W JP 9401455W WO 9507282 A1 WO9507282 A1 WO 9507282A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- unsubstituted
- compound
- lower alkyl
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
Definitions
- the present invention relates to a therapeutic agent for depression.
- R 'a represents hydrogen, lower alkyl or lower Arukanoi Le substituted or unsubstituted
- R 2a is hydrogen, lower alkenyl, substituted or unsubstituted cycloalkyl Le, a substituted or unsubstituted Fuyuniru, substituted or unsubstituted
- R 3a represents a substituted or unsubstituted 5-membered heterocyclic group
- X a represents 0, S, S (0), S ( 0) 2 or NR "(where, R" is either a hydrogen or a substituted or unsubstituted lower alkyl, becomes R 2 a and NR 4 a gar cord, 4 of 6-membered ring substituted or unsubstituted
- a a represents N or CR 5a (where R 5a represents hydrogen or a substituted or unsubstituted lower alky
- R 1 ′′ is hydrogen, substituted or unsubstituted lower alkyl or lower alkano.
- R represents a substituted or unsubstituted lower alkyl, lower alkenyl, lower alkynyl, substituted or unsubstituted phenyl or substituted or unsubstituted 5- or 6-membered heterocyclic group
- a b is N or CR 5b (wherein, represents a hydrogen or a substituted or unsubstituted lower alkyl) it is known that compounds represented by represents a] has a selective Adenoshin a 2 antagonism (JP-5- No. 97855 and Japanese Patent Laid-Open No. 5-155887).
- mice with aggressive behavior induced by clonidine administration conventional treatments for depression only show potentiating effects after 10 days of continuous administration [Journal-Off Neurolanole 'trans :; sshion ( J. Neural Transmission), 52, 189, 1981.
- the present invention provides a compound of the formula (I)
- R ′ represents hydrogen, substituted or unsubstituted lower alkyl or substituted or unsubstituted lower alkanol
- R 2 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted Or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl or substituted or unsubstituted heterocyclic group
- R : 1 represents a substituted or unsubstituted heterocyclic group
- X Is a single bond, 0, S, S (0), S (0), or NR 4 (wherein represents hydrogen or substituted or unsubstituted lower alkyl, or R 2 and NR are Represents a 4- to 6-membered substituted or unsubstituted nitrogen-containing saturated heterocyclic group), wherein A is N or CR 5 (wherein R is hydrogen or substituted or unsubsti
- the present invention relates to a method for treating depression, which comprises administering an effective amount of the triazine derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof.
- the present invention also relates to the use of a triazine derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a pharmacological composition useful for treating depression. :
- the present invention also relates to the use of a triazine derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof for treating depression.
- the present invention provides an effective amount of a triazine derivative represented by the above formula (I) or a pharmacologically acceptable salt thereof in a pharmacologically acceptable dosage form together with a pharmacologically acceptable carrier.
- Composition for the treatment of a disease comprising
- compound (I) the compound represented by the formula (I) is referred to as compound (I).
- the lower alkyl is a straight or branched chain having 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl. , Pentyl, neopentyl, hexyl, etc., and the lower alkanols include straight-chain or branched-chain C 1-7, for example, formyl, acetyl, propionyl, butyryl, isobutyryl, vivalyl, hexanoyl and the like.
- Examples of the lower alkenyl include straight-chain or branched-chain C 2 to C 6, for example, vinyl, 1-methylvinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-methyl-1-propane. Nyl, 1,3-butenyl, 1-pentenyl, 4-pentenyl, 1-hexenyl, 1,4-hexagenyl, 5-hexenyl
- Examples of cycloalkyl include cycloalkyl groups having 3 to 8 carbon atoms, for example, cycloalkyl groups such as cyclopropyl, cyclobutynole, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl; and carbon atoms having 7 to 12 carbon atoms.
- bicycloalkyl group such as norbornyl or carbon number? ⁇ 12 tricycloalkyl And the like.
- aryl include phenyl, naphthyl, indenyl, and anthryl
- aralkyl include those having 7 to 15 carbon atoms, such as benzyl, 1-phenylethyl, 2-phenylethyl, 2-phenylpropyl, and diphenylmethyl.
- heterocyclic group examples include furyl, phenyl, pyrrolyl, vinylil, thioviranyl, pyridyl, oxazolyl, thiazolyl, imidazolyl, pyrimidyl, triazinyl, indolyl, quinolyl, purinyl, benzoxazolyl, benzothiazolyl, and benzoimidazo.
- 4- to 6-membered nitrogen-containing saturated heterocyclic group examples include azetidino, pyrrolidino, morpholino, and thiomorpholino.
- Substituents of the same or different lower alkyl, lower alkanol, lower alkenyl, cycloalkyl, aryl, aralkyl, heterocyclic group and 4- to 6-membered nitrogen-containing saturated heterocyclic group may be the same or different.
- Examples include xy, carboxy, calvamoyl, lower alkanoyl, aloynole, aryl, halogen, nitro, amino, cyano, and trifluoromethyl.
- the lower alkyl portion of lower alkyl and hydroxy lower alkyl, halogeno lower alkyl, lower alkoxy, lower alkoxycarbonyl, lower alkylthio, lower alkyl sulfinyl, lower alkyl sulfonyl has the same definition as the above lower alkyl, and aryl and aryloxy
- the arylo moiety of halogenoaryloxy and arylo is the same as the above-mentioned definition of aryl
- the aralkyl moiety of aralkyloxy and halogenoaralkyloxy is the same as the definition of aralkyl
- lower alkanol is as defined above.
- the halogen part of halogen, halogeno lower alkyl, halogenoaryloxy, and halogenoaralkyloxy represents each atom of fluorine, chlorine, bromine, and iodine.
- Examples of the pharmaceutically acceptable salt of compound (I) include pharmaceutically acceptable acid addition salts, metal salts, ammonium salts, organic amine addition salts, amino acid addition salts and the like.
- Pharmaceutically acceptable acid addition salts of compound (I) include inorganic acid salts such as hydrochloride, sulfate, phosphate, acetate, maleate, fumarate, tartrate, and citrate.
- Examples of the pharmaceutically acceptable metal salts include alkali metal salts such as sodium salts and potassium salts, alkaline earth metal salts such as magnesium salts and calcium salts, aluminum salts, and zinc. And the like.
- Examples of pharmacologically acceptable ammonium salts include salts of ammonium and tetramethylammonium.
- Examples of pharmacologically acceptable organic amine addition salts include morpholine and Examples of addition salts such as lysine and pharmacologically acceptable amino acid addition salts include addition salts such as lysine, glycine, and phenylalanine.
- Compound (I), including a novel compound, can be produced by the method disclosed in the above publication or according to the method.
- the target compound in the production method can be isolated and purified by a purification method commonly used in organic synthetic chemistry, for example, filtration, extraction, washing, drying, concentration, recrystallization, various types of chromatography, and the like.
- the compound when it is desired to obtain a salt of compound (I), when compound (I) is obtained in the form of a salt, the compound may be purified as it is, and when it is obtained in a free form, it may be dissolved or dissolved in an appropriate solvent.
- the salt may be formed by suspending and adding an acid or a base to form a salt.
- Compound (I) and a pharmaceutically acceptable salt thereof may be present in the form of adducts with water or various solvents, and these adducts can also be used as the therapeutic agent of the present invention. .
- Some of the compounds (I) may have stereoisomers and optical isomers, but all possible stereoisomers, optical isomers and mixtures thereof are also used as the therapeutic agent of the present invention. be able to.
- Table 1 shows specific examples of the compound (I).
- the experiment was performed using two ddY male mice (Japan SLC) weighing 20 to 25 g per group. After adding Tween 80 [polyoxyethylene (20) sorbitan monooleate], the test compound was suspended in distilled water for injection (manufactured by Otsuka Pharmaceutical Co., Ltd.). (Manufactured by Sigma) was dissolved in physiological saline (manufactured by Otsuka Pharmaceutical) and used. A suspension containing the test compound or a suspension containing no test compound (control) was orally administered (0.1 ml per 10 g of mouse body weight), and clonidine 20 mg / kg was intraperitoneally administered 60 minutes after administration of the test compound. .
- mice The number of aggressive behaviors of mice was measured for 30 minutes immediately after clonidine administration. The effect was determined by comparing the number of times of challenge between the control group and the test compound administration group [significant difference test: Student's t-test]. The results are shown in Table 2. Number of attacks (number of counts:
- Compound (I) or a pharmacologically acceptable salt thereof has an effect of enhancing clonidine-induced aggressive behavior and is useful as a therapeutic agent for depression.
- the experiment was performed using 8 male ddY mice (Japan SLC) weighing 21-30 g per group.
- a solution prepared by diluting reserpine (Apobron Injection lmg: manufactured by Daiichi Pharmaceutical Co., Ltd.) with distilled water for injection (Otsuka Pharmaceutical Co., Ltd.) was intraperitoneally administered to mice (5 mg / kg).
- the test compound was orally administered 18 to 24 hours after the next day, and the locomotor activity was measured by Automex II (manufactured by Columbus) for 30 minutes from 60 minutes thereafter. The effect was determined by comparing the values of the control group and the test compound administration group.
- the significance test was performed by the Williams-Wilcoxon test.
- Table 3 shows the results. Test compound Spontaneous locomotion Name of administration group Dose of administration content (number of counts;
- the experiment was conducted using 10 ddY male mice (Japan SLC) weighing 21 to 26 g per group. During the pre-breeding period, the animals were bred in an animal room at a room temperature of 23 soils at 1 ° C and a humidity of 55 ⁇ 5%, and food and water were freely available. The animals used were those that showed abnormal responses in spontaneity, muscle tone, visibility, etc. in advance.
- the test compound was suspended in a 0.3% Tween 80 solution and orally administered 1 hour before the start of the test. To the negative control group, only 0.3% Tween 80 solution was orally administered with lOmg / kg.
- the measurement of immobility time is based on the Porsolt method [arch B.
- the experiment was conducted with 10 animals per group divided into 5 animals each in the morning and in the afternoon.
- the immobility time measurement was performed on two animals at the same time, and the observer was blinded to the presence / absence of the test compound and the dose of the test compound.
- a multiple comparison test of the control group administered with the solvent alone and the group administered with each test compound was performed using the Steat test method.
- Test compounds were orally administered to three male d d mice weighing 20 ⁇ 1 g per group. On the 7th day after administration, the state of death was observed, and the minimum lethal dose (MLD) value was determined.
- MLD lethal dose
- Compound 1 has an MLD value> 300 mg / k and is safe to use over a wide dosage range with low toxicity.
- Compound (I) or a pharmaceutically acceptable salt thereof can be used as it is or in various drug forms.
- the pharmaceutical composition of the present invention can be produced by uniformly mixing an effective amount of compound (I) or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable carrier as an active ingredient. Desirably, these pharmaceutical compositions are in unit dosage form suitable for administration orally or by injection.
- any useful pharmaceutically acceptable carrier can be used.
- Oral liquid preparations such as suspensions and syrups include water, sugars such as sucrose, sorbitol, fructose, glycols such as polyethylene glycol, propylene glycol, sesame oil, olive oil, It can be produced using oils such as soybean oil, preservatives such as P-hydroxybenzoic acid esters, and flavors such as strawberry flavor and peppermint.
- the injection can be prepared using a carrier comprising distilled water, a salt solution, a glucose solution, or a mixture of a salt solution and a glucose solution. At this time, it is prepared as a solution, suspension or dispersion using an appropriate dissolution aid or suspending agent according to a conventional method.
- Compound (I) or a pharmaceutically acceptable salt thereof can be administered orally or parenterally as an injection in the above-mentioned pharmaceutical form.
- Power varies depending on age, weight, symptoms, etc. Usually, 1 to 50 mg / kg per day is administered in 3 to 4 divided doses.
- a tablet having the following composition was prepared by a conventional method.
- Fine granules having the following composition were prepared by a conventional method.
- a forcepsel having the following composition was prepared by a conventional method.
- An injection having the following composition was prepared by a conventional method.
- a tablet having the following composition was prepared by a conventional method.
- a tablet having the following composition was prepared by a conventional method.
- an excellent therapeutic agent for depression can be provided.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Fuel-Injection Apparatus (AREA)
- Seal Device For Vehicle (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU75467/94A AU7546794A (en) | 1993-09-06 | 1994-09-02 | Depression remedy |
EP94925620A EP0667349B1 (en) | 1993-09-06 | 1994-09-02 | Depression remedy |
AT94925620T ATE198890T1 (en) | 1993-09-06 | 1994-09-02 | ANTIDEPRESSANTS |
US08/424,397 US5789407A (en) | 1993-09-06 | 1994-09-02 | Method of treating depression with certain triazine derivatives |
DE69426620T DE69426620T2 (en) | 1993-09-06 | 1994-09-02 | ANTIDEPRESSIVA |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP22143193 | 1993-09-06 | ||
JP5/221431 | 1993-09-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995007282A1 true WO1995007282A1 (en) | 1995-03-16 |
Family
ID=16766640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1994/001455 WO1995007282A1 (en) | 1993-09-06 | 1994-09-02 | Depression remedy |
Country Status (8)
Country | Link |
---|---|
US (1) | US5789407A (en) |
EP (1) | EP0667349B1 (en) |
AT (1) | ATE198890T1 (en) |
AU (1) | AU7546794A (en) |
CA (1) | CA2148502A1 (en) |
DE (1) | DE69426620T2 (en) |
ES (1) | ES2156901T3 (en) |
WO (1) | WO1995007282A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999043678A1 (en) * | 1998-02-24 | 1999-09-02 | Kyowa Hakko Kogyo Co., Ltd. | Remedies/preventives for parkinson's disease |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010087361A (en) | 1998-09-22 | 2001-09-15 | 히라타 다다시 | [1,2,4]-Triazolo[1,5-c]pyrimidine derivatives |
US6423844B1 (en) | 2001-06-06 | 2002-07-23 | The United States Of America As Represented By The Secretary Of The Navy | Process for making 1,2,4-triazolo[4,3-a][1,3,5]triazine-3,5,7-triamine |
US7834014B2 (en) | 2003-04-09 | 2010-11-16 | Biogen Idec Ma Inc. | A2a adenosine receptor antagonists |
EP1615930A2 (en) | 2003-04-09 | 2006-01-18 | Biogen Idec MA, Inc. | Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagonists |
US7674791B2 (en) | 2003-04-09 | 2010-03-09 | Biogen Idec Ma Inc. | Triazolopyrazines and methods of making and using the same |
CA3103068A1 (en) * | 2018-06-26 | 2020-01-02 | Zhejiang Vimgreen Pharmaceuticals, Ltd | Triazolotriazine derivatives as a2a receptor antagonists |
EP4083044A4 (en) * | 2019-12-26 | 2024-03-27 | Zhejiang Vimgreen Pharmaceuticals Ltd | Use of triazolotriazine derivative in treatment of diseases |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0597855A (en) * | 1990-05-29 | 1993-04-20 | Imperial Chem Ind Plc <Ici> | Azole derivative |
JPH05155887A (en) * | 1991-05-23 | 1993-06-22 | Imperial Chem Ind Plc <Ici> | Azole derivative |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4780464A (en) * | 1986-12-08 | 1988-10-25 | Warner-Lambert Company | (1,2,4)triazolo(4,3-a)quinoxaline-4-amines |
GB8901423D0 (en) * | 1989-01-23 | 1989-03-15 | Fujisawa Pharmaceutical Co | Pyrazolopyridine compound and processes for preparation thereof |
US5356894A (en) * | 1990-05-29 | 1994-10-18 | Rodney Peter W | Morpholinyl substituted [1,2,4]-triazolo[1,5-a]triazine as antagonist |
IT1260444B (en) * | 1992-01-24 | 1996-04-09 | Mario Brufani | DERIVATIVES OF 8- (1-AMINOCYCLOALKYL) 1,3-DIALKYLXANTINE, PREPARATION PROCEDURE AND THEIR PHARMACEUTICAL COMPOSITIONS ANTIDEPRESSANTS, NOOTROPICS AND PSYCHOSTIMULANTS |
-
1994
- 1994-09-02 ES ES94925620T patent/ES2156901T3/en not_active Expired - Lifetime
- 1994-09-02 WO PCT/JP1994/001455 patent/WO1995007282A1/en active IP Right Grant
- 1994-09-02 CA CA002148502A patent/CA2148502A1/en not_active Abandoned
- 1994-09-02 EP EP94925620A patent/EP0667349B1/en not_active Expired - Lifetime
- 1994-09-02 AU AU75467/94A patent/AU7546794A/en not_active Abandoned
- 1994-09-02 DE DE69426620T patent/DE69426620T2/en not_active Expired - Fee Related
- 1994-09-02 AT AT94925620T patent/ATE198890T1/en active
- 1994-09-02 US US08/424,397 patent/US5789407A/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0597855A (en) * | 1990-05-29 | 1993-04-20 | Imperial Chem Ind Plc <Ici> | Azole derivative |
JPH05155887A (en) * | 1991-05-23 | 1993-06-22 | Imperial Chem Ind Plc <Ici> | Azole derivative |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999043678A1 (en) * | 1998-02-24 | 1999-09-02 | Kyowa Hakko Kogyo Co., Ltd. | Remedies/preventives for parkinson's disease |
Also Published As
Publication number | Publication date |
---|---|
DE69426620D1 (en) | 2001-03-01 |
CA2148502A1 (en) | 1995-03-16 |
EP0667349A4 (en) | 1995-11-02 |
US5789407A (en) | 1998-08-04 |
DE69426620T2 (en) | 2001-06-21 |
EP0667349A1 (en) | 1995-08-16 |
EP0667349B1 (en) | 2001-01-24 |
ES2156901T3 (en) | 2001-08-01 |
ATE198890T1 (en) | 2001-02-15 |
AU7546794A (en) | 1995-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0666079B1 (en) | Remedy for parkinson's disease | |
EP2258372B1 (en) | A2A antagonists for use in the treatment of motor disorders | |
CA2913194C (en) | Bisulfate of janus kinase (jak) inhibitor and preparation method therefor | |
WO1999012546A1 (en) | Remedial agent for neural degeneration | |
WO1995007282A1 (en) | Depression remedy | |
WO2009156680A2 (en) | Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders | |
RU2544552C2 (en) | Therapeutic agent or preventive agent for neuropathic pain | |
HU198388B (en) | Process for producing pharmaceutical compositions containing amides of carboxylic acids for treating rheumatic and inflammatoric illnesses | |
JPH05132430A (en) | Use of glycine/nmda receptor ligand relating to therapy of drug dependence and withdrawal symptoms | |
US2817623A (en) | Tabernanthine, ibogaine containing analgesic compositions | |
CA2487905A1 (en) | Use of cgmp - stimulating compounds | |
CA2684174C (en) | Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease | |
ES2260061T3 (en) | PHARMACEUTICAL COMPOSITIONS FOR DISORDERS RELATED TO FOOD. | |
JP4022519B2 (en) | A preventive or therapeutic agent for pruritus | |
US20060205756A1 (en) | Antitussives | |
JPH11130672A (en) | Lipid peroxidation inhibitor | |
JPH0753375A (en) | Therapeutic agent for hepatopathy | |
JPWO2005011674A1 (en) | Preventive and / or therapeutic agent for bronchial asthma | |
JPWO2004063201A1 (en) | Schizophrenia treatment | |
JPH11130671A (en) | Aldose reductase inhibitor | |
JPWO2005007154A1 (en) | Preventive and / or therapeutic agent for pain | |
JPWO2005000293A1 (en) | Overactive bladder treatment for cerebrovascular disorders | |
AU2004296137A1 (en) | Preventive and/or therapeutic agent for higher brain dysfunction | |
JPH05279253A (en) | Preventing and treating agent for osteoporosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08424397 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2148502 Country of ref document: CA Ref document number: 1994925620 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1994925620 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1994925620 Country of ref document: EP |